A Multicentre Randomised Feasibility Study of Adjuvant Chemotherapy (CT) following Radical Primary Treatment for Transitional Cell Carcinoma (TCC) of the Bladder

INTERVENTION: Total Cystectomy or Radical RT +/‐ CT CT: Methotrexate 30 mg/m^2 (days 1, 15, 22) Vinblastine 3 mg/m^2 (days 2, 15, 22) Adriamycin 30 mg/m2 (day 2) Cisplatin 70 mg/m2 (day 2) every 28 days, maximum of three cycles CONDITION: Cancer of bladder (advanced) ; Cancer ; Bladder PRIMARY OUTCOME: Not provided at time of registration SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 1. Histologically confirmed invasive TCC of the bladder 2. Stage T2, T3a, T3b, T4a, N0 or T(any), N1/N2 3. Patient has undergone a complete resection at cystectomy or has received radical radiotherapy with curative intent 4. Fit enough to undergo combination chemotherapy 5. Creatinine clearance >60ml/min within 10 weeks of primary treatment 6. Haematological counts within 4 weeks before randomisation: White Blood Count (WBC) >3x10^9/l Platelets >100 x10^9/l Haemoglobin >10g/dl 7. Patient must be able to commence CT within 12 weeks of completion of primary treatment 8. Written informed consent